SARS-COV-2 Mpro conformational changes induced by covalently bound ligands

被引:0
|
作者
Ferreira, Glaucio Monteiro [1 ,2 ]
Kronenberger, Thales [2 ,3 ]
Tonduru, Arun Kumar [3 ]
Hirata, Rosario Dominguez Crespo [1 ]
Hirata, Mario Hiroyuki [1 ]
Poso, Antti [2 ,3 ]
机构
[1] Univ Sao Paulo, Sch Pharmaceut Sci, Dept Clin & Toxicol Anal, Sao Paulo, Brazil
[2] Univ Hosp Tubingen, Dept Oncol & Pneumonol, Internal Med 8, Tubingen, Germany
[3] Univ Eastern Finland, Fac Hlth Sci, Sch Pharm, Kuopio, Finland
基金
巴西圣保罗研究基金会;
关键词
COVID-19; main protease; M-pro; Molecular dynamics simulation; PROTEIN; MOLECULES;
D O I
暂无
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
SARS-CoV-2's main protease (M-pro) interaction with ligands has been explored with a myriad of crystal structures, most of the monomers. Nonetheless, Mpro is known to be active as a dimer but the relevance of the dimerization in the ligand-induced conformational changes has not been fully elucidated. We systematically simulated different Mpro-ligand complexes aiming to study their conformational changes and interactions, through molecular dynamics (MD). We focused on covalently bound ligands (N1 and N3, similar to 9 ls per system both monomers and dimers) and compared these trajectories against the apostructure. Our results suggest that the monomeric simulations led to an unrealistically flexible active site. In contrast, the Mpro dimer displayed a stable oxyanion-loop conformation along the trajectory. Also, ligand interactions with residues His41, Gly143, His163, Glu166 and Gln189 are postulated to impact the ligands' inhibitory activity significantly. In dimeric simulations, especially Gly143 and His163 have increased interaction frequencies. In conclusion, long-timescale MD is a more suitable tool for exploring in silico the activity of bioactive compounds that potentially inhibit the dimeric form of SARS-CoV-2 Mpro.
引用
收藏
页码:12347 / 12357
页数:11
相关论文
共 50 条
  • [31] Mechanistic Insight into SARS-CoV-2 Mpro Inhibition by Organoselenides: The Ebselen Case Study
    Madabeni, Andrea
    Nogara, Pablo Andrei
    Omage, Folorunsho Bright
    Rocha, Joao Batista Teixeira
    Orian, Laura
    APPLIED SCIENCES-BASEL, 2021, 11 (14):
  • [32] Microbial Natural Products as Potential Inhibitors of SARS-CoV-2 Main Protease (Mpro)
    Sayed, Ahmed M.
    Alhadrami, Hani A.
    El-Gendy, Ahmed O.
    Shamikh, Yara, I
    Belbahri, Lassaad
    Hassan, Hossam M.
    Abdelmohsen, Usama Ramadan
    Rateb, Mostafa E.
    MICROORGANISMS, 2020, 8 (07) : 1 - 17
  • [33] Crystal structures of main protease (Mpro) mutants of SARS-CoV-2 variants bound to PF-07304814
    Jiang, Haihai
    Zou, Xiaofang
    Zeng, Pei
    Zeng, Xiangyi
    Zhou, Xuelan
    Wang, Jie
    Zhang, Jin
    Li, Jian
    MOLECULAR BIOMEDICINE, 2023, 4 (01):
  • [34] Crystal structures of main protease (Mpro) mutants of SARS-CoV-2 variants bound to PF-07304814
    Haihai Jiang
    Xiaofang Zou
    Pei Zeng
    Xiangyi Zeng
    Xuelan Zhou
    Jie Wang
    Jin Zhang
    Jian Li
    Molecular Biomedicine, 4
  • [35] Computational and in vitro evaluation of sumac-derived ©Rutan compounds towards Sars-CoV-2 Mpro inhibition
    Kayumov, Muzaffar
    Marimuthu, Parthiban
    Razzokov, Jamoliddin
    Mukhamedov, Nurkhodja
    Asrorov, Akmal
    Berdiev, Nodir S.
    Ziyavitdinov, Jamolitdin F.
    Yashinov, Ansor
    Oshchepkova, Yuliya
    Salikhov, Shavkat
    Mirzaakhmedov, Sharafitdin
    FRONTIERS IN PHARMACOLOGY, 2025, 16
  • [36] Identification of potent compounds against SARs-CoV-2: An in-silico based drug searching against Mpro
    Hassam, Muhammad
    Bashir, Muhammad Arslan
    Shafi, Sarah
    Zahra, Noor-ul-Ain
    Khan, Kanwal
    Jalal, Khurshid
    Siddiqui, Hina
    Uddin, Reaz
    COMPUTERS IN BIOLOGY AND MEDICINE, 2022, 151
  • [37] Exploiting the co-crystal ligands shape, features and structure-based approaches for identification of SARS-CoV-2 Mpro inhibitors
    Yousaf, Numan
    Jabeen, Yaruq
    Imran, Muhammad
    Saleem, Muhammad
    Rahman, Moazur
    Maqbool, Abbas
    Iqbal, Mazhar
    Muddassar, Muhammad
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2023, 41 (23) : 14325 - 14338
  • [38] Discovery of Polyphenolic Natural Products as SARS-CoV-2 Mpro Inhibitors for COVID-19
    Kruger, Nadine
    Kronenberger, Thales
    Xie, Hang
    Rocha, Cheila
    Pohlmann, Stefan
    Su, Haixia
    Xu, Yechun
    Laufer, Stefan A. A.
    Pillaiyar, Thanigaimalai
    PHARMACEUTICALS, 2023, 16 (02)
  • [39] Design and Optimization of Novel Competitive, Non-peptidic, SARS-CoV-2 Mpro Inhibitors
    Jacobs, Leon
    van der Westhuyzen, Aletta
    Pribut, Nicole
    Dentmon, Zackery W.
    Cui, Dan
    D'Erasmo, Michael P.
    Bartsch, Perry W.
    Liu, Ken
    Cox, Robert M.
    Greenlund, Sujay F.
    Plemper, Richard K.
    Mitchell, Deborah
    Marlow, Joshua
    Andrews, Meghan K.
    Krueger, Rebecca E.
    Sticher, Zachary M.
    Kolykhalov, Alexander A.
    Natchus, Michael G.
    Zhou, Bin
    Pelly, Stephen C.
    Liotta, Dennis C.
    ACS MEDICINAL CHEMISTRY LETTERS, 2023, : 1434 - 1440
  • [40] Comprehensive fitness landscape of SARS-CoV-2 Mpro reveals insights into viral resistance mechanisms
    Flynn, Julia M.
    Samant, Neha
    Schneider-Nachum, Gily
    Barkan, David T.
    Yilmaz, Nese Kurt
    Schiffer, Celia A.
    Moquin, Stephanie A.
    Dovala, Dustin
    Bolon, Daniel N. A.
    ELIFE, 2022, 11